Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU’s First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

Halozyme Therapeutics, Inc. announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20.